{"id":"NCT02131636","sponsor":"Allergan","briefTitle":"Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea","officialTitle":null,"status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-05","primaryCompletion":"2014-11","completion":"2014-12","firstPosted":"2014-05-06","resultsPosted":"2016-03-10","lastUpdate":"2019-11-18"},"enrollment":440,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Erythema","Rosacea"],"interventions":[{"type":"DRUG","name":"AGN-199201","otherNames":[]},{"type":"DRUG","name":"Vehicle to AGN-199201","otherNames":[]}],"arms":[{"label":"AGN-199201","type":"EXPERIMENTAL"},{"label":"Vehicle","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of AGN-199201 once daily compared to vehicle for the treatment of persistent moderate to severe facial erythema associated with rosacea.","primaryOutcome":{"measure":"Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales","timeFrame":"Baseline, Day 29 (Hours 3, 6, 9, and 12)","effectByArm":[{"arm":"AGN-199201","deltaMin":11.9,"sd":null},{"arm":"Vehicle","deltaMin":5.5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":222},"commonTop":[]}}